Detailed Information on Publication Record
2018
Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy
DOBROTKOVÁ, Viera, Petr CHLAPEK, Pavel MAZÁNEK, Jaroslav ŠTĚRBA, Renata VESELSKÁ et. al.Basic information
Original name
Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy
Authors
DOBROTKOVÁ, Viera (703 Slovakia, belonging to the institution), Petr CHLAPEK (203 Czech Republic, belonging to the institution), Pavel MAZÁNEK (203 Czech Republic, belonging to the institution), Jaroslav ŠTĚRBA (203 Czech Republic, belonging to the institution) and Renata VESELSKÁ (203 Czech Republic, guarantor, belonging to the institution)
Edition
BMC Cancer, London, BioMed Central, 2018, 1471-2407
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30204 Oncology
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 2.933
RIV identification code
RIV/00216224:14310/18:00106966
Organization unit
Faculty of Science
UT WoS
000449121200004
Keywords in English
Retinoids; cell differentiation; retinoid resistance; retinoid sensitivity; predictive biomarkers; acute myeloid leukemia; pancreatic ductal adenocarcinoma; breast carcinoma; neuroblastoma
Tags
International impact, Reviewed
Změněno: 15/2/2019 16:19, prof. RNDr. Renata Veselská, Ph.D., M.Sc.
Abstract
V originále
For decades, retinoids and their synthetic derivatives have been well established anticancer treatments due to their ability to regulate cell growth and induce cell differentiation and apoptosis. Many studies have reported the promising role of retinoids in attaining better outcomes for adult or pediatric patients suffering from several types of cancer, especially acute myeloid leukemia and neuroblastoma. However, even this promising differentiation therapy has some limitations: retinoid toxicity and intrinsic or acquired resistance have been observed in many patients. Therefore, the identification of molecular markers that predict the therapeutic response to retinoid treatment is undoubtedly important for retinoid use in clinical practice. The purpose of this review is to summarize the current knowledge on candidate markers, including both genetic alterations and protein markers, for retinoid resistance and sensitivity in human malignancies.
Links
| NV15-34621A, research and development project |
|